In June 2017 Myomo Inc went Public on NYSE and became the first under Jumpstart Our Business Startups (JOBS) Act Regulation A+ to do so: an historic achievement. Previously doing business as Active Joint Brace, the underpinning technology of Myomo was originally developed from work funded by the MIT Deshpande Technogical Innovation Center. Myomo (NYSEMKT:MYO) is pioneering NeuroRobotics, a new category of non-invasive medical device technology to help people relearn how to move severely weak or partially paralyzed limbs. Originally an acronym for "Muscle-Motion," Myomo (pronounced MY-O-MO) was re-defined as "My-Own-Motion" by one of the first patients ever yo use the device. The firm offers Myomo mPower 1000, a portable lightweight functional arm brace for use in home and in clinical settings, which restores movement to a weakened arm as a result of neuromuscular damage caused or due to brain injury, including stroke, spinal cord injury, multiple sclerosis, cerebral palsy, muscular dystrophy, and traumatic brain injury. The company also provides PERL (Push, Eat, Reach, Lift) technique, a set of research-based treatment plans that integrate the mPower 1000 into functional repetitive task practice programs aiming to increase the functional activity; myGames, a virtual reality-based therapeutic training system to encourage brain injured patients with upper limb motor disorders to practice physical exercises; and myProgress, an Android-based connected health platform that tracks and measures progress while using the mPower 1000. The firm's mobility system is designed to enable individuals to self-initiate and control the movement of partially paralyzed limbs using their own muscle signals -- empowering individuals with a neuromuscular condition who have lost movement in a hand and arm to perform activities of everyday life. Myomo offers the MyoPro, a myoelectric elbow/wrist/hand orthosis (powered brace) to support the weak arm and enable patients to move an impaired hand and arm again.
